On June 25, 2018 in Warsaw the National Conference of the Association of People with Urinary Incontinence (NTM) "UroConti" will be held, entitled: "NTM 2018 - WHERE WE ARE, WHERE WE ARE HEADING?".HTA Consulting will also take part in the event - Piotr Miazga will present
4 of brands of infliximab (Remicade, Inflectra, Remisima and Flixabi) are reimbursement in Poland under 6 drug programs. Since the start of the reimbursement in 2012, the funding limit for 1 mg of infliximab has decreased by about 33%, while the volume-weighted average real price
AOTMiT (Polish HTA Agency) is preparing an opinion on the appropriateness of including 32 active substances from 26 limit groups (full list here) ) for reimbursement list for patients over 75 years of age. 90% of drugs containing the mentioned active substances within the analyzed
During the Congress of the Polish Diabetological Association taking place on 24-26 May 2018, a poster will be presented: "Continuous subcutaneous insulin infusion versus multiple daily injections in pregnant women with type 1 diabetes mellitus — a systematic review and meta-analysis of randomised controlled trials